Equillium, Inc. Form 8-K Summary
Business Context and Reporting Period
Equillium, Inc. filed a Form 8-K dated May 19, 2020, reporting results of its annual meeting of stockholders held on that date. The report was signed on May 21, 2020. The company’s common stock trades on The Nasdaq Global Market under the symbol EQ.
Meeting Participation and Key Results
- As of the April 1, 2020 record date, 17,683,965 common shares were outstanding and entitled to vote.
- 16,807,699 shares were represented in person or by proxy, equal to approximately 95.04% of outstanding shares.
- Class II director nominees Charles McDermott and Bruce D. Steel were elected to three-year terms expiring at the 2023 annual meeting.
- Charles McDermott received 12,508,303 votes for, 3,533,308 votes withheld, and 766,088 broker non-votes.
- Bruce D. Steel received 12,507,947 votes for, 3,533,664 votes withheld, and 766,088 broker non-votes.
- Stockholders ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020, with 16,780,476 votes for, 123 against, and 27,100 abstentions.
Financial Metrics and Material Changes
This filing does not report revenue, profit, cash flow, margins, debt, liquidity, operating guidance, or other financial results. It also does not identify material changes versus a prior comparable period. The principal reported developments were the election of two directors and ratification of the independent auditor.
Outlook, Risks, and Unusual Items
The filing provides no management outlook, operating commentary, new risk disclosures, contingencies, or unusual financial items. It identifies no changes to the company’s auditor; KPMG LLP was ratified for fiscal 2020.
Investor Verification Items
- Verify the final composition and term expirations of the Class II board seats.
- Confirm KPMG LLP’s appointment and review the company’s subsequent audited financial statements for fiscal 2020.
- Review later filings for financial performance, liquidity, financing activity, clinical or operating developments, and updated risk factors, none of which are addressed in this 8-K.